Strategic partnerships SynCardia operates under Picard Medical and has ongoing engagement with major cardiovascular and transplant audiences evidenced by frequent conference participation (ASAIO, ISHLT, ACC) and a focus on next-generation total artificial heart platforms, suggesting opportunities to align with hospitals, teaching centers, and research institutions for joint trials or trials expansion.

Hospital to home The Freedom Portable Driver enables discharge to home for stable patients, indicating a market opportunity to upsell portable system adoption within transplant programs and post-implant care pathways, as well as home-health integrations and remote monitoring capabilities.

Global regulatory reach With FDA and Health Canada approvals and active cross-border positioning via Picard Medical, there is potential to pursue expansion into additional regulated markets or expand access programs, as well as clinical data collaborations to support market entry in new regions.

Clinical proof and trials Extensive use in over 2,000 patients and ongoing publications from Emperor Total Artificial Heart research imply strong clinical credibility; sales outreach can emphasize outcomes data, real-world effectiveness, and post-market surveillance to drive adoption among leading transplant centers.

Scale and investment Revenue is in the multi-millions with modest funding relative to peers, signaling an opportunity to secure strategic partnerships, government or foundation grants, or venture-backed collaborations to scale manufacturing, distribution, and education programs for wider market penetration.